Skip to main content

Public profile

Canary Speech2 solutions in the public registryFounded2017Team size30-50HeadquartersProvo, Utah, USA

Browse developerscanaryspeech.com/

About

Canary Speech is the leading AI-powered voice biomarker company that uses patented real-time vocal analysis to detect health conditions. Our technology analyzes speech in seconds, identifying cognitive, behavioral, progressive neurological changes earlier than clinical screenings or noticeable symptoms.

AI Solutions

2 solutions from Canary Speech

Filter

Canary Speech Vocal Biomarker Model for Cognitive Health

Canary Speech
Stage
Production
Regulatory
HIPAA compliant, HITRUST E-1 Certified, ISO/IEC 27001:2022 and 42001:2023 Certified
Category
Clinical Decision Support
Setting
Ambulatory / Outpatient
Availability
USA; available for pilot and integration in select international markets

Canary Speech’s Cognitive Health model provides a cutting-edge standardized instrument designed to assist healthcare professionals in the analysis of vocal biomarkers that provide clinical decision support for Mild Cognitive Impairment and Alzheimer’s Disease in patients aged 50 and older. Our software utilizes an artificial intelligence algorithm to analyze speech patterns, providing clinicians actionable insights for early detection and ongoing management. Built for seamless integration, it functions as a clinical decision support tool within digital health workflows. Ultimately, clinicians are responsible for the diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease per the standard of care.

Details

Canary Speech Vocal Biomarker Model for Behavioral Health

Canary Speech
Stage
Production
Regulatory
HIPAA compliant, HITRUST E-1 Certified, ISO/IEC 27001:2022 and 42001:2023 Certified
Category
Clinical Decision Support
Setting
Ambulatory / Outpatient
Availability
USA; available for pilot and integration in select international markets

Canary Speech’s Behavioral Health model is a standardized instrument that provides clinical decision support to screen for Major Depressive Disorder and Generalized Anxiety Disorder in patients aged 18 and older. Our software utilizes an artificial intelligence algorithm to analyze speech patterns, providing clinicians with vocal biomarkers that provide actionable insights for early detection and ongoing management. Built for seamless integration, it functions within digital health workflows on any smart device. Ultimately, clinicians are responsible for the diagnosis of Major Depressive Disorder and Generalized Anxiety Disorder per the standard of care.

Details